Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.
Soligenix, Inc. reports developments as a late-stage biopharmaceutical company focused on rare diseases and public health medical countermeasures. Company news centers on HyBryte (synthetic hypericin), a visible-light activated therapy program for cutaneous T-cell lymphoma, and SGX945 (dusquetide) for Behçet's Disease, including clinical data, published study results and regulatory designations.
Updates also cover the Public Health Solutions segment, including RiVax ricin toxin vaccine candidate, filovirus vaccine programs, CiVax for COVID-19 and the ThermoVax heat-stabilization platform. Recurring announcements include operating and financial results, government-supported development activities, material agreements, shareholder voting matters and governance updates.
Soligenix, Inc. (SNGX) announced an Investor Webcast Event on September 10, 2020, to discuss its CiVax™ COVID-19 vaccine development using a thermostabilized glycoprotein platform. The prototype vaccine demonstrates strong immunity induction in preclinical studies, with notable safety in high-risk populations. Combined with its ability to remain stable at high temperatures, CiVax™ aims to meet urgent vaccination needs. Experts will present, followed by a Q&A session. The event invites questions beforehand and will provide a recording post-webcast.
Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical company focused on rare diseases, announced that its CFO, Jonathan Guarino, will present at the LD Micro Conference from September 1-4, 2020. Guarino's presentation is scheduled for September 4 at 9:40 AM ET. The conference will be held virtually. The company specializes in developing treatments like SGX301 for cutaneous T-cell lymphoma and vaccine candidates for various diseases. For more details on the conference, visit LD Micro Conference.
Soligenix, Inc. (SNGX) announced its Q2 2020 financial results and recent accomplishments. Revenue was $0.5 million, down from $1.4 million in Q2 2019. Net loss increased to $2.8 million, or ($0.10) per share, primarily due to higher R&D costs ($2.2 million). Positive developments include significant results from the Phase 3 FLASH trial for SGX301, with a statistically significant treatment response (p=0.04). Enrollment was completed for the SGX942 trial, with top-line results expected in Q4 2020. The company maintains a cash position of approximately $11.2 million, bolstered by government funding.
Soligenix, Inc. (SNGX) announced positive results from pre-clinical studies for its CiVax™ COVID-19 vaccine, demonstrating rapid onset immunity with antibody responses detected within 14 days of vaccination. Collaborations with the University of Hawaiʻi at Mānoa highlighted the efficacy of the CoVaccine HT™ adjuvant in enhancing immune responses. The vaccine aims to simplify distribution by being heat stable, which could alleviate cold chain logistics. The findings have been submitted for peer review in the journal npj Vaccines, reinforcing Soligenix's commitment to developing safe and effective vaccines for COVID-19.
Soligenix has completed patient enrollment for its Phase 3 DOM-INNATE study of SGX942, targeting oral mucositis in head and neck cancer patients. A total of 268 subjects were enrolled following positive interim analysis by an independent Data Monitoring Committee (DMC), which confirmed a beneficial drug effect. With top-line results expected in Q4 2020, SGX942 aims to address a significant unmet need as no FDA-approved treatment currently exists for this condition. The company maintains approximately $8 million in cash, positioning for further development milestones.
Soligenix (Nasdaq: SNGX) is set to join the Russell Microcap Index following the annual reconstitution, effective June 29, 2020. This inclusion enhances visibility among investors and is expected to positively impact the company's stock. The firm reported statistically significant results in its Phase 3 clinical trial for SGX301, targeting cutaneous T-cell lymphoma, and anticipates top-line results in Q4 2020 for SGX942 treatment of oral mucositis in head and neck cancer patients. These developments indicate a focus on addressing unmet medical needs in rare diseases.